Tafasitamab
Based on 2 publication(s) in Google Scholar
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.71%
- CAS No.: 1422527-84-1
- Masse moléculaire:147.42 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99113
Inebilizumab
-
HY-P9913
Rituximab
-
HY-P99761
Obexelimab
-
HY-P9966
Enoblituzumab
-
HY-P9963
Blinatumomab
-
HY-P99001
Human IgG1 kappa, Isotype Control
-
HY-70002
Enzalutamide
-
HY-130149
Adagrasib
-
HY-P9910
Obinutuzumab (FUT8-KO)
-
HY-141598
Datopotamab deruxtecan (solution)
-
HY-132253
Polatuzumab vedotin
-
HY-132254
Sacituzumab govitecan
Publications Citing Use of MedChemExpress (MCE) Tafasitamab
More
Activité biologique
Human IgG1 kappa
Human
CD19
Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NHL cell lines and primary CLL and MCL cells by γδ T cells
-
Concentration:
-
Incubation Time:2 h
-
Result:Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.
-
Cell Line:SU-DHL-6 cells
-
Concentration:
-
Incubation Time:72 h
-
Result:Showed potent antiproliferative effects on tumor cell.
-
Cell Line:SU-DHL-6 cells
-
Concentration:0-4 ng/mL
-
Incubation Time:48 h
-
Result:Showed potent antiproliferative effects due to caspase-induced apoptosis
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Disseminated Raji model[1].
-
Dosage:2.5 μg/kg
-
Administration:Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
-
Result:Showed antitumor activity in disseminated Raji model.
-
Animal Model:Disseminated Ramos model[1].
-
Dosage:10 mg/kg
-
Administration:Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
-
Result:Showed antitumor activity in disseminated Ramos model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-G2-kappa
ELISA, FACS, Functional assay
-
Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC50 for this effect is 29.1 ng/mL. -
Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 95.42 and 117.87 ng/mL.
Chemical Information
-
CAS No. 1422527-84-1
-
Appearance Liquid
-
Masse moléculaire 147.42 kDa
-
Color Colorless to light yellow
-
SMILES
[Tafasitamab]
-
Synonyms
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
Clin Chem Lab Med
2025 Sep 15. PMID: 40965972
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. [Content Brief]
[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tafasitamab Related Classifications
HY-P9981 Related Classifications
Powered by Bioz